Full Title:Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglobulin) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) - the PATH study Protocol IgPro20_3003
Principle Investigator:Norman Latov, MD, PhD
Contact Phone :(646) 962-2149
Additional Cornell Investigator:Russell L. Chin, MD Jennifer A. Langsdorf, MD
To read more about this study visit the ClinicalTrials.gov page here.